DEST Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Destiny Pharma plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.16 |
52 Week High | UK£0.84 |
52 Week Low | UK£0.13 |
Beta | 0.31 |
1 Month Change | -13.70% |
3 Month Change | -50.78% |
1 Year Change | -47.15% |
3 Year Change | -89.53% |
5 Year Change | -79.94% |
Change since IPO | -92.76% |
Recent News & Updates
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30Shareholder Returns
DEST | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | -0.7% | -0.6% |
1Y | -47.1% | -21.9% | 6.3% |
Return vs Industry: DEST underperformed the UK Biotechs industry which returned -21.9% over the past year.
Return vs Market: DEST underperformed the UK Market which returned 5.8% over the past year.
Price Volatility
DEST volatility | |
---|---|
DEST Average Weekly Movement | 12.8% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DEST's share price has been volatile over the past 3 months.
Volatility Over Time: DEST's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 24 | Chris Tovey | www.destinypharma.com |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma plc Fundamentals Summary
DEST fundamental statistics | |
---|---|
Market cap | UK£15.04m |
Earnings (TTM) | -UK£5.66m |
Revenue (TTM) | UK£831.55k |
18.1x
P/S Ratio-2.7x
P/E RatioIs DEST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DEST income statement (TTM) | |
---|---|
Revenue | UK£831.55k |
Cost of Revenue | UK£0 |
Gross Profit | UK£831.55k |
Other Expenses | UK£6.49m |
Earnings | -UK£5.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.059 |
Gross Margin | 100.00% |
Net Profit Margin | -680.30% |
Debt/Equity Ratio | 0% |
How did DEST perform over the long term?
See historical performance and comparison